blast phase chronic myelogenous leukemia, BCR-ABL1 positive

Summary

blast phase chronic myelogenous leukemia, BCR-ABL1 positive (MONDO:0006115) is a cancer and 90 clinical trials. Top therapeutic interventions include ponatinib, dexrazoxane, and imatinib. A subtype of chronic myeloid leukemia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 90

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	blast phase chronic myelogenous leukemia, BCR-ABL1 positive
Mondo ID	MONDO:0006115
EFO	EFO:1000131
MeSH	D001752
NCIT	C9110
SNOMED CT	413656006
UMLS	C0005699
MedGen	2281
GARD	0024298
Is cancer (heuristic)	yes

Also known as: blast crises · blast crisis · blast phase · blast phase chronic granulocytic leukaemia · blast phase chronic granulocytic leukemia · blast phase chronic myelocytic leukaemia · blast phase chronic myelocytic leukemia · blast phase chronic myelogenous leukaemia · blast phase chronic myelogenous leukemia · blast phase chronic myeloid leukaemia · blast phase chronic myeloid leukemia · blast phase CML · blast phases · blastic phase chronic granulocytic leukaemia · blastic phase chronic granulocytic leukemia · blastic phase chronic myelocytic leukaemia · blastic phase chronic myelocytic leukemia · blastic phase chronic myelogenous leukaemia · blastic phase chronic myelogenous leukemia · blastic phase chronic myeloid leukaemia (+6 more)

Data availability: 444 cell lines.

Disease family

This is a subtype of chronic myeloid leukemia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › leukemia › myeloid leukemia › chronic myeloid leukemia › blast phase chronic myelogenous leukemia, BCR-ABL1 positive

Related subtypes (2): familial chronic myelocytic leukemia-like syndrome, leukemia, myeloid, accelerated-phase

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

2 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Dasatinib Anhydrous	Approved (phase 4)
INTERFERON ALFA-2B	Approved (phase 4)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Ponatinib, Prednisone, Rituximab, Vincristine.

Clinical trials & evidence

Clinical trials

Clinical trials: 90.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE1	34
PHASE2	33
PHASE1/PHASE2	13
Not specified	8
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00799461	PHASE3	COMPLETED	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
NCT01428635	PHASE2/PHASE3	COMPLETED	Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
NCT01424982	PHASE2	ACTIVE_NOT_RECRUITING	Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
NCT02115295	PHASE2	RECRUITING	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
NCT03147612	PHASE2	ACTIVE_NOT_RECRUITING	Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia
NCT03263572	PHASE2	RECRUITING	Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
NCT03589729	PHASE2	RECRUITING	Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
NCT03934372	PHASE1/PHASE2	RECRUITING	Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
NCT04188405	PHASE2	ACTIVE_NOT_RECRUITING	Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
NCT04258943	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
NCT00015834	PHASE1/PHASE2	COMPLETED	STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00023920	PHASE2	TERMINATED	Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia
NCT00034684	PHASE1/PHASE2	COMPLETED	Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
NCT00052598	PHASE1/PHASE2	TERMINATED	Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant
NCT00054431	PHASE2	COMPLETED	Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia
NCT00068718	PHASE1/PHASE2	COMPLETED	Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
NCT00084916	PHASE2	COMPLETED	CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
NCT00089011	PHASE2	COMPLETED	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
NCT00101816	PHASE2	COMPLETED	Dasatinib (BMS-354825) in Subjects With Myeloid Blast Phase Chronic Myeloid Leukemia Resistant to or Intolerant of Imatinib Mesylate
NCT00105001	PHASE2	COMPLETED	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
NCT00114959	PHASE2	TERMINATED	Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
NCT00309907	PHASE2	COMPLETED	Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
NCT00381550	PHASE2	COMPLETED	3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
NCT00387426	PHASE2	TERMINATED	Sunitinib in Treating Patients With Idiopathic Myelofibrosis
NCT00390793	PHASE2	COMPLETED	Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
NCT00489203	PHASE2	COMPLETED	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
NCT00540995	PHASE1/PHASE2	TERMINATED	Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
NCT00636909	PHASE2	COMPLETED	Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
NCT00702403	PHASE1/PHASE2	COMPLETED	Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
NCT00763763	PHASE2	COMPLETED	Imatinib Mesylate With Vincristine and Dexamethasone in Acute Lymphoblastic Leukemias With BCR-ABL Positive
NCT00795769	PHASE2	COMPLETED	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
NCT00860574	PHASE2	COMPLETED	Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia
NCT01044745	PHASE2	TERMINATED	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
NCT01056614	PHASE2	COMPLETED	Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
NCT01093586	PHASE2	COMPLETED	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT01159067	PHASE2	TERMINATED	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
NCT01427881	PHASE2	COMPLETED	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies
NCT01564277	PHASE2	TERMINATED	Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies
NCT01652014	PHASE2	WITHDRAWN	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
NCT01670084	PHASE2	WITHDRAWN	Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PONATINIB	4	8
DEXRAZOXANE	4	6
IMATINIB	4	5
VORINOSTAT	4	5
DASATINIB ANHYDROUS	4	4
BOSUTINIB	4	3
ELTROMBOPAG	4	3
NILOTINIB	4	3
2-MERCAPTOETHANESULFONIC ACID	4	2
BLINATUMOMAB	4	2
CLADRIBINE	4	2
ONDANSETRON	4	2
BECLOMETHASONE DIPROPIONATE	4	1
COBIMETINIB	4	1
COPANLISIB	4	1
DACOMITINIB	4	1
DACOMITINIB ANHYDROUS	4	1
DAROLUTAMIDE	4	1
DECITABINE	4	1
DEFERASIROX	4	1
EDETATE CALCIUM DISODIUM MONOHYDRATE	4	1
ENASIDENIB	4	1
ENTRECTINIB	4	1
FOSCARNET	4	1
FOSCARNET SODIUM	4	1
GANCICLOVIR	4	1
GEMTUZUMAB OZOGAMICIN	4	1
GILTERITINIB	4	1
IDARUBICIN	4	1
IDELALISIB	4	1